Business
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised for Phase 2 Trial
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised for Phase 2 Trial Initiation Later in 2H23Company Completes $5 million Equity Raise, Extending Cash Runway into 3Q24SEATTLE, WA / ACCESSWIRE / August 10, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2023 and provided a business update, including duration of remission (DOR) data for its lead clinical candidate, APVO436.Business HighlightsAPVO436 DOR DataYazan Madanat, MD, Assistant Professor in the Department of Internal Medicine, and Eugene P. Frenkel, M.D. Scholar in Clinical Medicine at the Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center said, \"There is an urgent need to improve therapeutic options in the AML space as older patients unfit for intensive chemotherapy generally have poor prognosis, response to available treatment and overall quality of life. The combination of azacitidine, venetoclax with APVO436 response rates and durability data are encouraging and show that this therapeutic (APVO436) has the potential to impact the treatment paradigm and ultimately improve outcomes for patients with AML.\"The Company reported positive and clinically meaningful DOR results evaluating its bispecific AML drug candidate, APVO436, in combination with the emerging standard of care venetoclax + azacytidine in venetoclax treatment naïve patients. Duration, the length of remission time following treatment with the triplet of venetoclax + azacitidine and APVO436, is an important measure of clinical success as it shows how long treatment benefit lasts for each patient and for each group of patients.Outcomes are as follows:9 of 11 (82%) patients responded sufficiently for inclusion in the DOR analysis3 of the 9 patients moved to stem cell transplant with treatment. This is the best outcome for patients because stem cell transplant offers the best probability for survivalOne patient experienced a sustained complete remission and remained on study drug for eight cycles, the maximum allowed per the protocolThe duration of remission data is clini...